Rasdal Andrew P 4
4 · OBALON THERAPEUTICS INC · Filed May 2, 2018
Insider Transaction Report
Form 4
Rasdal Andrew P
DirectorPresident & CEO
Transactions
- Award
Common Stock
2018-04-30$3.27/sh+2,987$9,767→ 457,058 total
Footnotes (1)
- [F1]These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).